Radiopharm Theranostics Shares Plunge 21% on Dilutive Capital Raise

Shares of Radiopharm Theranostics Ltd (NASDAQ:RADX) plummeted 21% on Friday following the company's announcement that it plans to raise up to $13 million in capital through concurrent offerings in the U.S. and Australia. The move is expected to dilute the ownership stake of current investors, prompting a significant sell-off in the market.

Details of the Offering

Radiopharm has entered into an agreement with accredited institutional investors in the U.S. for a registered direct offering, according to a company statement. The U.S. portion of the deal aims to raise approximately $4.1 million in gross proceeds before fees.

Key terms of the U.S. transaction include:

• The issuance of 1,281,646 American Depositary Shares (ADSs) at a price of $3.16 per ADS.
• A concurrent private placement of unregistered warrants to purchase up to an additional 1,281,646 ADSs.
• The warrants will have an exercise price of $3.79 per ADS and will expire on July 31, 2029, becoming exercisable upon shareholder approval.

Ad

Each ADS represents 300 of the company's ordinary shares. The offering is expected to close on or about July 28, 2026, with H.C. Wainwright & Co. acting as the exclusive U.S. placement agent.

Market Impact and Context

The sharp decline in Radiopharm's stock price is a typical market reaction to a dilutive financing event. By issuing new shares at a set price, the company increases its total share count, which reduces the ownership percentage of existing shareholders. For clinical-stage biotechnology firms like Radiopharm, which are not yet generating revenue, raising capital through share offerings is a common method to fund ongoing research and clinical trials.

Radiopharm is focused on developing radiopharmaceuticals for cancer treatments in areas with high unmet medical needs. The company, which is listed on both the Nasdaq and the Australian Securities Exchange (ASX:RAD), has a clinical program that includes one Phase 2 trial and five Phase 1 trials targeting various solid tumor cancers.